Journal
CANCER IMMUNOLOGY IMMUNOTHERAPY
Volume 60, Issue 8, Pages 1161-1171Publisher
SPRINGER
DOI: 10.1007/s00262-011-1012-8
Keywords
PIVAC 10; Immune escape; MHC I; Oxidative stress; Myeloid-derived suppressor cells; Regulatory T cells
Categories
Funding
- Swedish Cancer Society
- Swedish Medical Research Council
- Cancer Society of Stockholm
- European Union
- Karolinska Institutet
- Lars-Hiertas Memorial Foundation
- Stockholm City Council
Ask authors/readers for more resources
The field of tumor immunology has made great progress in understanding tumor immune interactions. As a consequence a number of immuno-therapeutic approaches have been successfully introduced into the clinic and a large number of promising therapeutic strategies are investigated in ongoing clinical trials. Evaluation of anti-tumor immunity in such trials as well as in animal models has shown that tumor escape from immune recognition and tumor-mediated suppression of anti-tumor immunity can pose a significant obstacle to successful cancer therapy. Here, we review mechanisms of tumor immune escape and immune-subversion with a focus on the research interests in our laboratory: loss of MHC class I on tumor cells, increased oxidative stress, recruitment of myeloid-derived suppressor cells, and regulatory T cells.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available